Poets | Bookstore | Poem of the Day | Top 40 | Search | Comments | Privacy
December 21st, 2014 - we have 234 poets, 8,025 poems and 279,673 comments.
Analysis and comments on To make a prairie it takes a clover and one bee, by Emily Dickinson

1 2 [3] 4 5 6 

Comment 40 of 60, added on August 19th, 2013 at 1:49 PM.
lbhzlDgkoCJ

rCSjiV Im thankful for the blog.Thanks Again. Fantastic.

great link buildng from Kyrgyz Republic (Kyrgyzstan)
Comment 39 of 60, added on August 2nd, 2013 at 4:28 PM.
EolLYtBKyGg

eno8Dv I value the post.Really looking forward to read more. Awesome.

best news from Algeria
Comment 38 of 60, added on May 28th, 2013 at 2:41 AM.
RPiHypbQdfvNKtUzl

xG9itb Say, you got a nice blog. Awesome.

seo service from Kazakhstan
Comment 37 of 60, added on May 28th, 2013 at 2:00 AM.
cNcKiHmGjAOobqn

XImrlt Very good article post.Really thank you! Really Cool.

seo service from Brunei Darussalam, Negara
Comment 36 of 60, added on May 27th, 2013 at 6:22 AM.
VjsVDqeXyx

DwcHzj wow, awesome blog article. Great.

seo service from Thailand
Comment 35 of 60, added on May 25th, 2013 at 11:47 PM.
Coffee break proves downfall for hatchet-carrying hitchhiker vtq

The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223
dichloride) to treat men with symptomatic late-stage (metastatic)
castration-resistant prostate cancer that has spread to bones but not to
other organs. It is intended for men whose cancer has spread after
receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found
below the bladder and in front of the rectum. The male sex hormone
testosterone stimulates the prostate tumors to grow. According to the
National Cancer Institute, an estimated 238,590 men will be diagnosed with
prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product¡¯s
prescription drug user fee goal date of Aug. 14, 2013, the date the agency
was scheduled to complete review of the drug application. The FDA reviewed
Xofigo under the agency¡¯s priority review program, which provides for an
expedited review of drugs that appear to provide safe and effective therapy
when no satisfactory alternative therapy exists, or offer significant
improvement compared to marketed products.

¡°Xofigo binds with minerals in the bone to deliver radiation directly to
bone tumors, limiting the damage to the surrounding normal tissues,¡± said
Richard Pazdur, M.D., director of the Office of Hematology and Oncology
Products in the FDA¡¯s Center for Drug Evaluation and Research. ¡°Xofigo is
the second prostate cancer drug approved by the FDA in the past year that
demonstrates an ability to extend the survival of men with metastatic
prostate cancer.¡±

In August 2012, the FDA approved Xtandi to treat men with metastatic
castration-resistant prostate cancer that has spread or recurred, even with
medical or surgical therapy to minimize testosterone. Xtandi is approved
for patients who have previously been treated the chemotherapy drug
docetaxel.

Xofigo¡¯s safety and effectiveness were evaluated in a single clinical
trial of 809 men with symptomatic castration-resistant prostate cancer that
spread to bones but not to other organs. Patients were randomly assigned to
receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a
pre-planned interim analysis showed men receiving Xofigo lived a median of
14 months compared to a median of 11.2 months for men receiving placebo. An
exploratory updated analysis conducted later in the trial confirmed
Xofigo¡¯s ability to extend overall survival.

The most common side effects reported during clinical trials in men
receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg,
ankle or foot. The most common abnormalities detected during blood testing
included low levels of red blood cells (anemia), lymphocytes
(lymphocytopenia), white blood cells (leukopenia), platelets
(thrombocytopenia) and infection-fighting white blood cells (neutropenia).




gandigoBligma from Saudi Arabia
Comment 34 of 60, added on May 25th, 2013 at 1:43 PM.
Venturi, US Open champion and CBS analyst, dies hbb

The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223
dichloride) to treat men with symptomatic late-stage (metastatic)
castration-resistant prostate cancer that has spread to bones but not to
other organs. It is intended for men whose cancer has spread after
receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found
below the bladder and in front of the rectum. The male sex hormone
testosterone stimulates the prostate tumors to grow. According to the
National Cancer Institute, an estimated 238,590 men will be diagnosed with
prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product¡¯s
prescription drug user fee goal date of Aug. 14, 2013, the date the agency
was scheduled to complete review of the drug application. The FDA reviewed
Xofigo under the agency¡¯s priority review program, which provides for an
expedited review of drugs that appear to provide safe and effective therapy
when no satisfactory alternative therapy exists, or offer significant
improvement compared to marketed products.

¡°Xofigo binds with minerals in the bone to deliver radiation directly to
bone tumors, limiting the damage to the surrounding normal tissues,¡± said
Richard Pazdur, M.D., director of the Office of Hematology and Oncology
Products in the FDA¡¯s Center for Drug Evaluation and Research. ¡°Xofigo is
the second prostate cancer drug approved by the FDA in the past year that
demonstrates an ability to extend the survival of men with metastatic
prostate cancer.¡±

In August 2012, the FDA approved Xtandi to treat men with metastatic
castration-resistant prostate cancer that has spread or recurred, even with
medical or surgical therapy to minimize testosterone. Xtandi is approved
for patients who have previously been treated the chemotherapy drug
docetaxel.

Xofigo¡¯s safety and effectiveness were evaluated in a single clinical
trial of 809 men with symptomatic castration-resistant prostate cancer that
spread to bones but not to other organs. Patients were randomly assigned to
receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a
pre-planned interim analysis showed men receiving Xofigo lived a median of
14 months compared to a median of 11.2 months for men receiving placebo. An
exploratory updated analysis conducted later in the trial confirmed
Xofigo¡¯s ability to extend overall survival.

The most common side effects reported during clinical trials in men
receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg,
ankle or foot. The most common abnormalities detected during blood testing
included low levels of red blood cells (anemia), lymphocytes
(lymphocytopenia), white blood cells (leukopenia), platelets
(thrombocytopenia) and infection-fighting white blood cells (neutropenia).

12312
12312

gandigoBligma from Ghana
Comment 33 of 60, added on May 25th, 2013 at 12:02 PM.
YnBUlFWTINgHPMKSphB

15soVA Great article.

good seo from Kenya
Comment 32 of 60, added on May 25th, 2013 at 9:31 AM.
SykOrJbpmVq

eFabZ4 Thanks for sharing, this is a fantastic blog article.Really thank
you! Really Cool.

good seo from Malaysia
Comment 31 of 60, added on May 25th, 2013 at 8:17 AM.
JxvbhOyvILU

xtFSWS Say, you got a nice article post.Really thank you! Keep writing.

good seo from Uzbekistan

This poem has been commented on more than 10 times. Click below to see the other comments.
1 2 [3] 4 5 6 
Share |


Information about To make a prairie it takes a clover and one bee,

Poet: Emily Dickinson
Poem: 1755. To make a prairie it takes a clover and one bee,
Volume: Complete Poems of Emily Dickinson
Year: 1955
Added: Jan 9 2004
Viewed: 95 times


Add Comment

Do you have any comments, criticism, paraphrasis or analysis of this poem that you feel would assist other visitors in understanding this poem better? If they are accepted, they will be added to this page of American Poems. Together we can build a wealth of information, but it will take some discipline and determination.

Do not post questions, pleas for homework help or anything of the sort, as these types of comments will be removed. The proper place for questions is the poetry forum.

Please note that after you post a comment, it can take up to an hour before it is visible on the website! Rest assured that your comment is not lost, so don't enter your comment again.

Comment on: 1755. To make a prairie it takes a clover and one bee,
By: Emily Dickinson

Name: (required)
E-mail Address: (required)
Country:
Show E-mail Address:
Yes No
Subject:
Poem Comments:

Poem Info

Dickinson Info
Copyright © 2000-2012 Gunnar Bengtsson. All Rights Reserved. Links | Bookstore